Report Highlights

Oral Thin Films in the United States: Market Overview

The U.S. oral thin film market reached USD 0.92 billion in 2024, making it the largest national market for the dosage form and accounting for close to half of global film revenue. Unlike the global norm, where generic substitution and Asia Pacific manufacturing scale dominate, the American segment rewards branded, patent-protected reformulations. Sponsors license film platforms and secure distinct labels rather than competing on production cost, and regulatory exclusivity, not manufacturing volume, sets the competitive pace.

Structurally, the market is shaped by FDA approval pathways rather than factory capacity. Sympazan (clobazam) and Libervant (diazepam) show how a film reformulation of an existing controlled substance can secure its own label, pediatric exclusivity and reimbursement position. Dissolvable films also suit patients who cannot swallow tablets, placing the format between oral tablets and injectables in hospital and retail practice. Growth therefore tracks clinical indications rather than generic volume.

Growth Drivers Behind U.S. Oral Thin Films

Dysphagia affects an estimated 15 million American adults, and older patients in skilled nursing facilities frequently cannot swallow tablets reliably. The Census Bureau projects the population aged 65 and over to exceed 70 million by 2030, expanding the Medicare Part D base that reimburses dosage-form alternatives. Films dissolve on the tongue without liquid compounding, which lowers pharmacy labor and dosing error, and CMS nursing home quality standards reinforce this preference.

Opioid use disorder treatment and pediatric seizure rescue form the second and third drivers. SAMHSA's National Survey on Drug Use and Health reports more than 48 million Americans aged 12 and older with a substance use disorder, while Medicaid coverage of buprenorphine films remains broad across states. Sympazan and Libervant, approved for pediatric epilepsy, demonstrate that buccal and sublingual films capture caregiver preference for rapid, non-injectable rescue dosing.

Restraints and Entry Barriers in American Oral Thin Films

The principal barrier is regulatory. A 505(b)(2) application must reference an approved listed drug and typically requires bioequivalence or pharmacokinetic bridging studies costing between USD 15 million and USD 25 million. Under Hatch-Waxman, a Paragraph IV certification triggers a 30-month stay on approval, and controlled substances such as clobazam add DEA scheduling and registration obligations under the Controlled Substances Act.

Distribution and pricing form the second barrier. Pharmacy benefit managers frequently place film presentations on higher formulary tiers than tablet equivalents and require prior authorization, while 340B covered entities limit hospital margins. From 2026, Medicare drug price negotiation under the Inflation Reduction Act will reset net prices for high-spend Part D products, compressing returns for film sponsors reliant on premium pricing.

Opportunities for Oral Thin Films in the U.S.

Near-term opportunity concentrates in emergency rescue. Sublingual epinephrine film for anaphylaxis addresses an estimated 32 million Americans with food allergies, and an addressable segment of roughly USD 140 million exists among insured patients carrying auto-injectors. Entrants able to demonstrate faster onset and needle-free administration can target caregivers, school nurses and first responders as distinct buying groups.

Neurology offers a second pathway. Migraine films that replicate triptan efficacy in a dosage form suited to nausea address USD 90 million of acute migraine spend. Pediatric exclusivity under the Best Pharmaceuticals for Children Act adds six months of protection to qualifying products, making pediatric neurology indications a priority for first-to-file film applicants.

Market at a Glance

Leading Market Participants

• Aquestive Therapeutics
• Indivior
• LTS Lohmann Therapie-Systeme
• Cure Pharmaceutical
• Hikma Pharmaceuticals
• Catalent
• Sandoz
• Zydus Lifesciences
• Dr. Reddy's Laboratories
• Lupin

Regulatory and Policy Environment

The Food, Drug, and Cosmetic Act governs approval through FDA's Center for Drug Evaluation and Research, which reviews 505(b)(2) films under PDUFA VII commitments with a standard 10-month goal following submission. Manufacturing must comply with 21 CFR Parts 210 and 211, and the Drug Supply Chain Security Act requires interoperable electronic product tracing across all trading partners, with full enforcement from November 2024. The DEA oversees scheduling under the Controlled Substances Act.

The Inflation Reduction Act of 2022 introduces CMS-led price negotiation for Medicare Part D, with first negotiated prices effective January 2026. Federal incentives remain indirect: the Orphan Drug Tax Credit under Internal Revenue Code Section 45C provides a 25 percent credit on qualified clinical testing expenses for orphan indications. Sponsors should align filing timelines with USP compendial standards for dosage form testing and with state Medicaid prior-authorization rules.

Long-Term Outlook for U.S. Thin Film Therapeutics

By 2032 the U.S. oral thin film market is projected to reach USD 1.75 billion, growing at an 8.4 percent CAGR from the 2025 base year. Growth will concentrate in pediatric epilepsy, opioid use disorder maintenance and epinephrine rescue, where film presentations hold clinical differentiation. Market share will consolidate around sponsors holding multiple 505(b)(2) approvals, while generic film entry remains limited by patent thickets and formulation complexity.

Pricing pressure from IRA negotiation and PBM rebate programs will reshape the economic model by the early 2030s, favoring low-cost manufacturing partnerships. Contract development organizations with validated film casting and coating lines in the U.S. will gain share as sponsors seek domestic supply resilience. Expect more partnerships between film technology licensors and large generic manufacturers by 2030.